Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03550391 · ClinicalTrials.gov registry record · Phase 3
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
A Phase 3 study of Brain Metastases, sponsored by Canadian Cancer Trials Group.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 206
- Enrollment target
- 20
- Study locations
NCT03550391 is a Phase 3 study of Brain Metastases that is actively recruiting participants, run by Canadian Cancer Trials Group. The registered enrollment target is 206 participants, roughly in line with the 210-participant average among 67 other Brain Metastases trials with a reported enrollment target. The trial reports 20 study locations across 3 states.
The verdict
NCT03550391, a Phase 3 study of Brain Metastases, is actively recruiting participants, sponsored by Canadian Cancer Trials Group.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 206 participants
- Enrollment target
- 20
- Study locations
Study Summary
Stereotactic radiosurgery (SRS) is a commonly used treatment for brain tumors. It is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to small spots in the brain while excluding the surrounding normal brain. Whole brain radiation therapy with hippocampal avoidance (HA-WBRT) is when radiation therapy is given to the whole brain, while trying to decrease the amount of radiation that is delivered to the area of the hippocampus. The hippocampus is a brain structure that is important for memory. Memantine is a drug that is given to help relieve symptoms that can be caused by WBRT, including problems with memory and other mental symptoms. Health Canada, the regulatory body that oversees the use of drugs in Canada, has not approved the sale or use of memantine in combination with WBRT to treat this kind of cancer, although they have allowed its use in this study.
Conditions Studied
Interventions
- DRUG Memantine
- RADIATION Hippocampal-avoidant (HA-WBRT) Radiotherapy
- PROCEDURE Stereotactic Radiosurgery (SRS)
Study Locations (20)
California
- City of Hope Corona - Corona
- City of Hope Comprehensive Cancer Center - Duarte
- City of Hope at Irvine Lennar - Irvine
- UC San Diego Moores Cancer Center - La Jolla
- City of Hope Antelope Valley - Lancaster
- UC Irvine Health/Chao Family Comprehensive Cancer Center - Orange
- Kaiser Permanente-Rancho Cordova Cancer Center - Rancho Cordova
- Rohnert Park Cancer Center - Rohnert Park
- The Permanente Medical Group-Roseville Radiation Oncology - Roseville
- South Sacramento Cancer Center - Sacramento
- Kaiser Permanente Medical Center - Santa Clara - Santa Clara
- City of Hope South Pasadena - South Pasadena
- Kaiser Permanente Cancer Treatment Center - South San Francisco
- City of Hope South Bay - Torrance
- City of Hope Upland - Upland
Florida
- Boca Raton Regional Hospital - Boca Raton
- UM Sylvester Comprehensive Cancer Center at Coral Gables - Coral Gables
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach - Deerfield Beach
Arizona
- University of Arizona Cancer Center-Orange Grove Campus - Tucson
- University of Arizona Cancer Center-North Campus - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 2018-11-22 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03550391
The ClinicalTrials.gov registry entry for NCT03550391 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 206 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 210-participant average among 67 other Brain Metastases trials with a reported enrollment target. The listed sponsor is Canadian Cancer Trials Group, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Brain Metastases appearing as the primary indexed condition, and to 3 interventions - of which Memantine is the first listed.
NCT03550391 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT03550391 about?
NCT03550391 is a clinical study titled "Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases". Stereotactic radiosurgery (SRS) is a commonly used treatment for brain tumors. It is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to small spots in the brain while excluding the surrounding normal brain. Whole brain radiation therapy...
What is the current status of trial NCT03550391?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 206 participants. The study started on 2018-11-22. Estimated completion is 2027-12-31.
What conditions does trial NCT03550391 study?
This clinical trial studies the following conditions: Brain Metastases.
What interventions are being tested in trial NCT03550391?
The interventions under investigation include: Memantine (DRUG), Hippocampal-avoidant (HA-WBRT) Radiotherapy (RADIATION), Stereotactic Radiosurgery (SRS) (PROCEDURE).
Who is sponsoring clinical trial NCT03550391?
This trial is sponsored by Canadian Cancer Trials Group, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03550391 being conducted?
This trial has 20 study locations across Arizona, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Metastases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)
ACTIVE NOT RECRUITING · Phase 3
-
18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery
RECRUITING · Phase 1
-
Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery
RECRUITING · Phase 1
-
Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
RECRUITING · Phase 1
-
Trial of Differential Margins in Single Isocenter Radiosurgery of Brain Metastases
RECRUITING · NA
-
Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.